63 related articles for article (PubMed ID: 18258054)
1. Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.
Jiang L; Yuan CM; Hubacheck J; Janik JE; Wilson W; Morris JC; Jasper GA; Stetler-Stevenson M
Br J Haematol; 2009 Apr; 145(2):173-9. PubMed ID: 19236377
[TBL] [Abstract][Full Text] [Related]
2. Receptor-directed therapy of T-cell leukemias and lymphomas.
Morris JC; Waldmann TA; Janik JE
J Immunotoxicol; 2008 Apr; 5(2):235-48. PubMed ID: 18569395
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of Rhodococcus lung abscess and empyema thoracis in a heart transplant recipient.
Namsiripongpun W; Yingchoncharoen T; Ngodngamthaweesuk M; Sukprapruet A; Naratreekoon B; Bruminhent J
Transpl Infect Dis; 2023 Dec; 25(6):e14140. PubMed ID: 37697912
[TBL] [Abstract][Full Text] [Related]
4. Brief Tale of a Bacteraemia by Rhodococcus equi, With Concomitant Lung Mass: What Came First, the Chicken or The Egg?
Savini V; Salutari P; Sborgia M; Mancini I; Masciarelli G; Catavitello C; Astolfi D; D'Amario C; Fioritoni G; Spadaro A; D'Antonio D
Mediterr J Hematol Infect Dis; 2011; 3(1):e2011006. PubMed ID: 21625310
[TBL] [Abstract][Full Text] [Related]
5. Infectious complications associated with monoclonal antibodies and related small molecules.
Salvana EM; Salata RA
Clin Microbiol Rev; 2009 Apr; 22(2):274-90, Table of Contents. PubMed ID: 19366915
[TBL] [Abstract][Full Text] [Related]
6. Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.
Meeuse JJ; Sprenger HG; van Assen S; Leduc D; Daenen SM; Arends JP; van der Werf TS
Emerg Infect Dis; 2007 Dec; 13(12):1942-3. PubMed ID: 18258054
[TBL] [Abstract][Full Text] [Related]
7. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H.
Dearden CE; Matutes E; Cazin B; Tjønnfjord GE; Parreira A; Nomdedeu B; Leoni P; Clark FJ; Radia D; Rassam SM; Roques T; Ketterer N; Brito-Babapulle V; Dyer MJ; Catovsky D
Blood; 2001 Sep; 98(6):1721-6. PubMed ID: 11535503
[TBL] [Abstract][Full Text] [Related]
8. Epstein-barr virus-positive diffuse large B-cell lymphoma during therapy with alemtuzumab for T-cell prolymphocytic leukemia.
Sohani AR; Ferry JA; Chang PS; Abramson JS
J Clin Oncol; 2010 Feb; 28(5):e69-72. PubMed ID: 19917859
[No Abstract] [Full Text] [Related]
9. Guillain-Barré syndrome after use of alemtuzumab (Campath) in a patient with T-cell prolymphocytic leukemia: a case report and review of the literature.
Abbi KK; Rizvi SM; Sivik J; Thyagarajan S; Loughran T; Drabick JJ
Leuk Res; 2010 Jul; 34(7):e154-6. PubMed ID: 20362332
[No Abstract] [Full Text] [Related]
10. Alemtuzumab.
Ravandi F; O'Brien S
Expert Rev Anticancer Ther; 2005 Feb; 5(1):39-51. PubMed ID: 15757437
[TBL] [Abstract][Full Text] [Related]
11. [Rhodococcus equi pulmonary abscess in HIV infection].
About I; Castan B; Capdeville J; Vanche J
Rev Med Interne; 1996; 17(5):410-4. PubMed ID: 8763102
[TBL] [Abstract][Full Text] [Related]
12. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders.
Martin SI; Marty FM; Fiumara K; Treon SP; Gribben JG; Baden LR
Clin Infect Dis; 2006 Jul; 43(1):16-24. PubMed ID: 16758413
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of action and resistance to monoclonal antibody therapy.
Villamor N; Montserrat E; Colomer D
Semin Oncol; 2003 Aug; 30(4):424-33. PubMed ID: 12939711
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
